-
Mashup Score: 0
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax in patients with relapsed/refractory MCL. A safety run-in (SRI) cohort was conducted to inform…
Source: Journal of Hematology & OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases - Journal of Hematology & Oncology - 3 year(s) ago
The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). They are generally associated…
Source: Journal of Hematology & OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases [Mar 21, 2012] Véronique Gelsi-Boyer et al. J Hematology & Oncology https://t.co/7FB7qkg31p #mpnsn #leusm #MDSsm #AMLsm #PrecisionMedicine
-
-
Mashup Score: 1Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases - Journal of Hematology & Oncology - 3 year(s) ago
The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). They are generally associated…
Source: Journal of Hematology & OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases [Mar 21, 2012] Véronique Gelsi-Boyer et al. J Hematology & Oncology https://t.co/7FB7qkg31p #mpnsn #leusm #MDSsm #AMLsm #PrecisionMedicine https://t.co/fo6agdsqkt
-
-
Mashup Score: 0Combination strategies to maximize the benefits of cancer immunotherapy - Journal of Hematology & Oncology - 3 year(s) ago
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. This review article will…
Source: Journal of Hematology & OncologyCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A Review published in the Journal of Hematology & Oncology discusses the relationship between cancer immune response and mechanisms of resistance to immunotherapy. https://t.co/t20kpgcg5d
-
-
Mashup Score: 1Combination strategies to maximize the benefits of cancer immunotherapy - Journal of Hematology & Oncology - 3 year(s) ago
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. This review article will…
Source: Journal of Hematology & OncologyCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A Review published in the Journal of Hematology & Oncology discusses the relationship between cancer immune response and mechanisms of resistance to immunotherapy. https://t.co/cXVicJEL3e
-
-
Mashup Score: 4Combination strategies to maximize the benefits of cancer immunotherapy - Journal of Hematology & Oncology - 3 year(s) ago
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. This review article will…
Source: Journal of Hematology & OncologyCategories: Latest Headlines, UrologyTweet-
Herculean effort for this #JHO review on combination immunotherapy strategies to overcome cancer resistance to checkpoint inhibitors. Grateful to be part of the team with @Zihai #ChongxianPan @JHOeditor et al. https://t.co/anm71Swe8V https://t.co/z3JEW3MhA3
-
-
Mashup Score: 2Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond - Journal of Hematology & Oncology - 3 year(s) ago
The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical approval with significant implications in extending patient survival and advancing closer to the goal of a cure, especially in areas of immunotherapy such as…
Source: Journal of Hematology & OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond #mmsm https://t.co/N1eAi1q8HP
-
-
Mashup Score: 12NK cell-based cancer immunotherapy: from basic biology to clinical development - Journal of Hematology & Oncology - 3 year(s) ago
Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively unsophisticated cues for activation, NK cell has…
Source: Journal of Hematology & OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
On Deck: NK cell-based cancer immunotherapy: from basic biology to clinical development | Journal of Hematology & Oncology | Full Text #biotwitter #CarTcell #BiTe #leuksm #gbm https://t.co/lXrUiO9ZkJ
-
-
Mashup Score: 1Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review - Journal of Hematology & Oncology - 3 year(s) ago
Extranodal natural killer/T cell lymphoma (ENKTL), nasal type, presents predominantly as a localized disease involving the nasal cavity and adjacent sites, and the treatment of localized nasal ENKTL is a major issue. However, given its rarity, there is no standard therapy based on randomized controlled trials and therefore a lack of consensus on the treatment of localized nasal ENKTL. Currently…
Source: Journal of Hematology & OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review | Journal of Hematology & Oncology | Full Text https://t.co/odOUZr4HQI
-
-
Mashup Score: 5Targeted therapy in advanced non-small cell lung cancer: current advances and future trends - Journal of Hematology & Oncology - 3 year(s) ago
Lung cancer remains the leading cause of cancer-related mortality in both men and women in the US and worldwide. Non-small cell lung cancer is the most common variety accounting for 84% of the cases. For a subset of patients with actionable mutations, targeted therapy continues to provide durable responses. Advances in molecular and immunohistochemical techniques have made it possible to usher…
Source: Journal of Hematology & OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Comprehensive “review article” on currently available & upcoming targeted therapy for Non-Small Cell #LungCancer #NSCLC by outstanding #HemOnc fellow: Dr. Umair Majeed @oumair @MayoCancerCare #CancerEducation #LCSM https://t.co/bgRBm60BJi https://t.co/fe8MXpZDyR
-
https://t.co/2VV5nS3K9G